What I Wish I’d Known at Diagnosis: Lessons From People With IBD

Receiving a diagnosis of inflammatory bowel disease (IBD) can feel overwhelming. The period immediately following diagnosis is often marked by uncertainty, confusion about treatment options, and questions about what daily life will look like. While every person’s experience with Crohn’s disease or ulcerative colitis is unique, certain lessons emerge repeatedly from those who have lived with these conditions for years.

Understanding That Remission Is the Goal

Many people newly diagnosed with IBD assume that treatment aims simply to reduce symptoms. While symptom relief matters, the clinical goal is achieving and maintaining remission, which means controlling the underlying inflammation in the gut lining. Symptoms such as abdominal pain, diarrhoea, or fatigue do not always reflect the level of inflammation present. It is possible to feel relatively well whilst inflammation persists, or to experience symptoms when inflammation is controlled. This is why objective measures such as faecal calprotectin, blood tests, endoscopy, and imaging are used to assess disease activity rather than relying on symptoms alone.

Remission allows the gut lining to heal, reduces the risk of complications such as strictures or fistulas, and improves long-term outcomes. Treatment decisions are based on achieving this deeper control, not just making you feel better in the short term.

Medication Is Not the Enemy

A common concern after diagnosis is the prospect of long-term medication, particularly biologics or immunosuppressants. Many people worry about side effects or express a preference to try diet and lifestyle changes first. Whilst diet, sleep, and stress management all play supportive roles, they cannot replace the immunological control that medication provides. Delaying or avoiding treatment can allow inflammation to progress, increasing the risk of irreversible bowel damage.

Medications used in IBD work by targeting specific pathways in the inflammatory response. Biologics, for example, block proteins such as tumour necrosis factor alpha (TNF-alpha) or interleukins that drive chronic inflammation. These treatments are monitored carefully, and side effects, whilst possible, are generally manageable with regular blood tests and clinical oversight. Starting effective treatment early improves the likelihood of achieving remission and can prevent the need for surgery or more aggressive intervention later.

Inflammation Is Not Always Visible or Predictable

Gut inflammation in IBD does not always produce clear or consistent symptoms. Some people feel unwell when inflammation is mild, whilst others remain asymptomatic despite significant disease activity. This discrepancy can make it difficult to know when to seek medical advice or adjust treatment. Regular monitoring through blood tests, stool samples, and periodic endoscopy provides a clearer picture of what is happening inside the gut, independent of how you feel day to day.

Relying solely on symptoms to guide decisions can lead to under-treatment. Persistent low-level inflammation, even when symptoms are mild or absent, contributes to long-term complications. Trusting objective measures and maintaining open communication with your gastroenterology team is essential.

Food Is Individual, Not Universal

Diet is one of the most discussed topics among people with IBD, but there is no single diet that works for everyone. Certain foods may trigger symptoms during a flare, whilst others are well tolerated in remission. Common triggers include high-fibre foods, dairy, caffeine, alcohol, and spicy or fatty meals, but individual tolerance varies widely.

Dietary changes can help manage symptoms and support overall wellbeing, but they do not replace medical treatment. Restrictive diets should be approached cautiously, particularly if they risk nutritional deficiencies. Working with a registered dietitian who specialises in IBD can help identify personal triggers, ensure adequate nutrient intake, and avoid unnecessary restrictions.

Fatigue Is Real and Often Underestimated

Fatigue is one of the most common and debilitating symptoms of IBD, yet it is frequently overlooked or dismissed. It can persist even when other symptoms are controlled and is not always proportional to disease activity. Contributing factors include chronic inflammation, anaemia, poor sleep, medication side effects, malabsorption of nutrients, and the psychological burden of living with a chronic condition.

Addressing fatigue requires a multifaceted approach. Blood tests can identify anaemia or deficiencies in iron, vitamin B12, vitamin D, or folate. Optimising sleep, maintaining regular physical activity where possible, and managing stress all play a role. Fatigue should be discussed openly with your healthcare team, as it can significantly affect quality of life and may indicate that treatment needs adjusting.

Flares Are Not Always Your Fault

It is common to feel responsible when a flare occurs, particularly if you have been adhering carefully to treatment and lifestyle advice. Whilst factors such as stress, infection, certain medications, or dietary choices can sometimes contribute, flares often happen despite best efforts. IBD is a chronic inflammatory condition with an unpredictable course, influenced by immune system behaviour, genetics, and environmental factors that are not entirely within your control.

Understanding this can reduce feelings of guilt or frustration. Flares are part of the natural history of IBD and do not mean you have failed. They do, however, signal the need for medical review and possible treatment adjustment. Early intervention during a flare can prevent prolonged or severe episodes.

Communication With Your Healthcare Team Matters

Building a collaborative relationship with your gastroenterology team is one of the most valuable steps you can take. This means being honest about symptoms, medication adherence, side effects, and concerns. It also means asking questions when you do not understand something and engaging actively in decisions about your care.

Many people hesitate to contact their IBD team between appointments, fearing they are overreacting or wasting time. However, early communication about worsening symptoms can prevent complications. Knowing when and how to reach your team, understanding your treatment plan, and keeping track of your own monitoring results empowers you to participate more fully in managing your condition.

Practical Takeaways

• Trust that remission, not just symptom relief, is the clinical target and the best way to protect your gut long term.
• Start treatment when advised, rather than delaying in the hope that diet or lifestyle alone will be sufficient.
• Use objective measures such as blood tests and faecal calprotectin to guide decisions, not symptoms alone.
• Work with a dietitian to identify personal food triggers and maintain balanced nutrition without unnecessary restriction.
• Discuss fatigue openly with your healthcare team and address contributing factors such as anaemia or sleep disturbance.
• Recognise that flares can occur despite your best efforts and are not a reflection of failure.
• Communicate regularly and honestly with your gastroenterology team, and ask questions when uncertain.

Conclusion

The early months after an IBD diagnosis are a learning process. Understanding the difference between symptoms and inflammation, accepting the role of medication, and recognising the individuality of the condition are all lessons that take time to internalise. Whilst the condition is chronic, effective treatment, regular monitoring, and informed self-management allow many people to achieve stable remission and maintain quality of life.

References

1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365(18):1713-1725. doi:10.1056/NEJMra1102942

1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741-1755. doi:10.1016/S0140-6736(16)31711-1

1. Narula N, Wong ECL, Dulai PS, et al. Comparative effectiveness of biologics for endoscopic healing of the ileum and colon in Crohn’s disease. Am J Gastroenterol. 2022;117(7):1106-1117. doi:10.14309/ajg.0000000000001795

1. Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015;47(2):172-179. doi:10.1038/ng.3176

1. Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017;152(2):351-361. doi:10.1053/j.gastro.2016.09.046

1. Barberio B, Zamani M, Black CJ, et al. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(5):359-370. doi:10.1016/S2468-1253(21)00014-5

1. Chavarría C, Casanova MJ, Chaparro M, et al. Prevalence and factors associated with fatigue in patients with inflammatory bowel disease: a multicentre study. J Crohns Colitis. 2019;13(8):996-1002. doi:10.1093/ecco-jcc/jjz018

1. Jairath V, Feagan BG. Global burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020;5(1):2-3. doi:10.1016/S2468-1253(19)30358-9

This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.

More from Gastro Living